Income Statement Revenue (ttm): 130.61M Revenue Per Share (ttm): 3.263 Qtrly Revenue Growth (yoy): 35.50% Gross Profit (ttm): 79.06M EBITDA (ttm): 944.00K Net Income Avl to Common (ttm): -26.58M Diluted EPS (ttm): -0.66 http://finance.yahoo.com/q/ks?s=VOLC
EPS Trends Current Qtr Jun-08 Next Qtr Sep-08 Current Year Dec-08 Next Year Dec-09 Current Estimate -0.03 -0.01 -0.01 0.22 7 Days Ago -0.03 -0.01 -0.01 0.22 30 Days Ago -0.03 -0.01 -0.01 0.22 60 Days Ago -0.03 -0.01 -0.01 0.22 90 Days Ago -0.03 -0.01 -0.01 0.22 http://finance.yahoo.com/q/ae?s=VOLC Near the turning point into profitability?
Merriman Curhan Ford analyst Jose J. Haresco also maintained a positive outlook on the company, reaffirming a "Buy" rating. New product launches, relationships with drug-coated stent partners and its sales force will all help to drive growth over the next two years.
"We believe Volcano's continued strong execution even in the face of decreasing PCI procedures speaks volumes about its growth potential," he said.
PCI procedures, commonly called angioplasty, often involve the use of a stent to prop open a clogged artery. The procedures have been on the decline since possible safety issues arose last year over drug-coated stents.
Haresco said the company's recently approved Revolution catheter and a partnership with Johnson & Johnson should help it take more market share from competitor Boston Scientific Corp.
Comments on seekingalpha.com volcano-corporation-q1-2008-earnings-call-transcript?: As a result a growing number of interventional cardiologist are using IVUS for enhanced diagnosis and therapy guidance to prevent stent placement related complications. The stable flow clinical data with an evidence that the American College of Cardiology where we announced the formal launch of the new s5i integrated system with phased array and Rotational catheters and integrated FFR Fractional Flow Reserve pressure guide virus. In addition Volcano has displayed at the best of our distribution partners GE, Philips, Siemens and Toshiba. There are also a number of live cases utilizing IVUS and clinical presentations throughout the meeting. Dr. Antonio Colombo discussed his routine use of IVUS to confirm stent expansion and apposition and Dr. Jeff Dysart outlined data involving more than 6000 patients from the Washington Hospital Center that demonstrate the improved clinical outcomes and lower rates of stent thrombosis in patients where IVUS guidance was used. There is also a great deal of interest surrounding the potential of our new required OCT technology as we conducted product feed back sessions with key opinion leaders and Dr. Mark Feldman made a presentation on OCT technology in the main arena. A second factor driving IVUS adoption is our ability to make IVUS simple and faster and easier to perform through innovative and differentiated technology. We used to take 12 steps now it takes 2 and the procedures can be completed in 2 to 3 minutes versus 12 to 15 minutes all with improved imaging capabilities: http://seekingalpha.com/article/76235-volcano-corporation-q1-2008-earnings-call-transcript?source=homepage_transcripts_sidebar&page=2